PharmaFocus Today – Page 63 – media

IBS Rates Nearly Doubled During the Pandemic

By Dennis Thompson HealthDay ReporterMONDAY, July 1, 2025 (HealthDay News) — The COVID-19 pandemic took a toll on Americans’ guts, researchers report. Gut disorders like irritable bowel syndrome (IBS) increased significantly during the COVID-19 pandemic, a new study says. Rates of IBS nearly doubled among U.S. adults, rising from around 6% in May 2020 to about 11% in May 2022, results show. Other gut health problems like constipation also increased, researchers report in the journal Neurogastroenterology & Motility. “Rates of digestive issues such as irritable bowel syndrome and chronic idiopathic constipation rose significantly,” lead researcher Dr. Christopher Almario, a gastroenterologist at Cedars-Sinai Medical Center in Los Angeles, said in a news release. “These findings underscore the significant toll the pandemic has taken on digestive health,” Almario added. Conditions like IBS and chronic constipation are driven by complex interactions between the gut and the nervous system, researchers said in background notes. ...
- Source: drugdu
- 96
- July 3, 2025
Kangtai Biological’s 13-valent pneumococcal vaccine obtains Türkiye’s GMP certificate and related products are expected to enter the local market

Recently, the 13-valent pneumococcal polysaccharide conjugate vaccine of Minhai Biopharmaceuticals (hereinafter referred to as Kangtai Minhai), a wholly-owned subsidiary of Kangtai Biological, obtained the GMP certification certificate issued by the Turkish Food and Drug Administration. The acquisition of this certificate indicates that the production facilities, processes, quality control and quality management systems of Minhai Biopharmaceuticals PCV13 vaccine are in compliance with Turkey’s strict pharmaceutical production quality management standards, and also indicates that the product has the necessary conditions for access to the local Turkish market. Turkey is a “crossroads” connecting the Eurasian continent, and its geographical location has significant locational advantages. The country’s economic development is growing rapidly, and its GDP ranks among the top 20 in the world. In 2024, Turkey’s total population will be about 85.66 million, and the number of newborns in 2023 will be about 950,000. In recent years, the country’s public health level and medical ...
- Source: drugdu
- 169
- July 3, 2025
Zhifei Biotech has obtained another invention patent certificate

On the evening of July 1, the company and its wholly-owned subsidiaries, Beijing Zhifei Green Bamboo Biopharmaceutical Co., Ltd. and Anhui Zhifei Longcom Biopharmaceutical Co., Ltd., recently obtained the National Intellectual Property Rights of the People’s Republic of China.An invention patent certificate issued by the Bureau, the patent name is “A primer pair and its application in BCG-CpG-DNA adjuvant quality control method”, patent number ZL202211426011.7, patent certificate number 8029182, and the application date is November 14, 2022. The company stated that the above invention patent was applied for and obtained during the research and development of the freeze-dried recombinant tuberculosis vaccine (AEC/BC02) independently developed by the company and still in the research stage, and will be used in the company’s related products under research. The acquisition of this patent certificate will not have a significant impact on the company’s recent production and operation, but it will help to further improve ...
- Source: drugdu
- 112
- July 3, 2025
Zai Lab’s Phase III clinical trial of this drug achieved positive results

On June 30, Zai Lab announced that the main data of the Phase III study of bemazumab for FGFR2b-positive first-line gastric cancer achieved positive results . Zai Lab said that the detailed results of the study will be announced at a future medical conference, but this achievement is expected to redefine the standard treatment of first-line gastric cancer and bring new hope of survival to gastric cancer patients. 01 New breakthrough The FORTITUDE-101 study is a global multicenter, randomized, double-blind, placebo-controlled clinical trial designed to evaluate the efficacy and safety of bematuzumab combined with mFOLFOX6 chemotherapy versus placebo combined with mFOLFOX6 as first-line treatment. The study was conducted in 300 research centers in 37 countries around the world, with a total of 547 patients enrolled. The study met its primary endpoint of overall survival (OS) at a pre-specified interim analysis, with bematumab plus chemotherapy demonstrating a statistically significant and clinically ...
- Source: drugdu
- 110
- July 3, 2025
The first domestic generic version of Lifelast Eye Drops (5%) was approved for marketing

On June 30, the official website of the National Drug Evaluation Center showed that Kanghong Pharmaceutical’s lifetilast eye drops (trade name Langyueming) were exclusively launched in China as a Class 3 new drug, which will provide a new option for dry eye treatment. With the popularization of electronic devices, the acceleration of the aging process and bad eye habits, the incidence of dry eyes in China has been increasing year by year. The number of people suffering from dry eyes or dry eye symptoms in China exceeds 300 million. According to a research report by the China Economic Industry Research Institute, the domestic dry eye drug market will reach 4.79 billion yuan in 2024, with a compound growth rate of 16.17% from 2020 to 2024, providing a huge market space for the development of dry eye drugs. Inflammatory response is the driving factor of ocular surface damage in the pathological ...
- Source: drugdu
- 111
- July 3, 2025
Apple may abandon its self-developed AI models; Zuckerberg announces restructuring of Meta AI team | Global technology early participation

NO.1 Apple may abandon self-developed AI models According to foreign media sources, Apple is considering abandoning its self-developed internal model and using Anthropic or OpenAI’s artificial intelligence (AI) technology to drive the new version of Siri. Insiders revealed that Apple has contacted these two companies to discuss deploying their Large Language Model (LLM) on Apple’s own cloud infrastructure for testing. Comment: This collaboration may indicate that Apple’s self-developed progress in the AI field is not as expected and requires external forces to accelerate development. NO.2 Moderna Influenza Vaccine Phase III Clinical Trial Successfully Completed On Monday, US vaccine manufacturer Moderna announced that its experimental influenza vaccine based on mRNA had a stronger immune response than the existing vaccine in a phase III trial, which paved the way for the approval of its COVID-19/influenza combined vaccine. Comment: This achievement not only brings new hope to the influenza vaccine market, but ...
- Source: drugdu
- 165
- July 2, 2025
The Hang Seng Hong Kong Stock Connect Innovative Drug Index is about to be revised; Hengrui Pharmaceutical’s alopecia areata drug has been approved for market launch | Medical Early Reference

NO.1 Hang Seng Hong Kong Stock Connect Innovative Drug Index is about to be revised, explicitly excluding CXO companies On June 30th, the Hang Seng Hong Kong Stock Connect Innovation Drug Index announced a revised compilation plan, adding a rule to exclude CXO (pharmaceutical outsourcing) companies. According to the new compilation plan, all the constituent stocks of the revised index are innovative pharmaceutical companies, making it one of the first innovative pharmaceutical indices tracked by ETFs to achieve a purity of 100%. Pang Yaping, General Manager of the Index Research Department of E Fund, stated that CXO mainly provides services and does not directly acquire the core intellectual property rights of innovative drugs. Generally, CXO does not participate in the patent development and commercialization of innovative drugs and does not obtain patent authorization benefits. Therefore, after excluding CXO, the Hang Seng Hong Kong Stock Connect Innovative Drug Index can focus ...
- Source: drugdu
- 443
- July 2, 2025
FDA Approves Benlysta Autoinjector for Pediatric Patients With Active Lupus Nephritis

By Lori Solomon HealthDay ReporterMONDAY, June 30, 2025 (HealthDay News) — The U.S. Food and Drug Administration has approved an autoinjector of Benlysta (belimumab) for subcutaneous injection in patients ≥5 years of age with active lupus nephritis who are receiving standard therapy. Benlysta (200 mg/mL), a B-lymphocyte stimulator-specific inhibiting monoclonal antibody, is the first and only approved biologic for both systemic lupus erythematosus and lupus nephritis. It is not recommended in patients with severe active central nervous system lupus. The most common major adverse reactions seen with Benlysta were serious infections, some of which were fatal. The most common adverse reactions (≥5 percent) were nausea, diarrhea, fever, inflammation of the nasal passages and throat, bronchitis, insomnia, pain in extremity, depression, migraine, and injection site reactions. “In children, lupus tends to be more aggressive and severe than it is in adults. The symptoms can be more intense, and the disease ...
- Source: drugdu
- 123
- July 2, 2025
‘Pill-On-A-String’ Could Revolutionize Testing For Throat Cancer

By Dennis Thompson HealthDay ReporterMONDAY, June 30, 2025 (HealthDay News) — The thought of swallowing a pill on a thread isn’t the most pleasant notion, but it could be a vastly better alternative for people at increased risk of throat cancer, a new study says. For nearly 20 years, U.K. resident Duncan Cook has had regular endoscopies to monitor his case of Barrett’s esophagus, a condition in which acid reflux damages cells and can lead to throat cancer. Then researchers offered him another option: Swallow a capsule that dissolves in the stomach to release a small sponge. Using an attached string, health care professionals draw the sponge back up the throat, lightly scraping cells off the esophagus along the way. “The first time I had the sponge, I was a bit nervous. It’s quite a big pill to swallow, but it’s much better than going for endoscopies,” Cook, 57, ...
- Source: drugdu
- 114
- July 2, 2025
Hybribio obtained 1 invention patent

July 1, Hybribio(300639) announced that the company and its subsidiaries have recently obtained authorization for an invention patent. The patent is called “Method, device and equipment for processing genome copy number variation analysis data”, the patent number is 202510354669.9, and the country of grant is China. The patent holders include Guangzhou Cap Medical Laboratory Co., Ltd., Guangzhou Cap Medical Laboratory Development Co., Ltd. and the company itself. The invention relates to the field of bioinformatics and provides a data screening logic and conditions that can accurately present the CNV results of the whole genome. This method can reduce interference information and improve the accuracy and readability of the interpretation of the test results. The company said that obtaining this patent is in line with its development strategy and will not have a significant impact on the current business situation, but it will help improve intellectual property rights.system to enhance core ...
- Source: drugdu
- 135
- July 2, 2025

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.